Merck stock pulls back after rally as cancer vaccine and Keytruda drive Q2 2026 growth
Published on 08/29/2026 at 08:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (ISIN US58933Y1055) stock has given back part of a recent double-digit rally after investors cheered promising phase 3 data for its personalized cancer vaccine in combination with Keytruda, even as the latest quarter showed solid but measured growth in oncology-driven revenue as of August 28, 2026.
The shares recently traded around $147.60 on the New York Stock Exchange, down 1.30 percent in the latest session after touching an all-time high near $151 earlier in the day per a real-time quote snapshot from a market portal as of August 28, 2026, 11:02 a.m. ET.
That move came on the heels of news that a personalized cancer vaccine developed with a partner significantly extended the time high-risk melanoma patients remained cancer-free when used alongside Keytruda compared with Keytruda alone in a phase 3 trial involving more than 1,000 participants, according to a detailed report on the trial results dated August 29, 2026.
For investors, the combination of a fresh oncology catalyst and a steady Q2 2026 earnings base raises the question of how much of Merck's long-term growth story is already reflected in the current valuation and what future milestones might justify further upside.
Q2 2026 numbers show oncology-led growth
In the second quarter of 2026, Merck reported total sales of $16.6 billion, an increase of 5 percent year over year, supported by continued expansion of its immuno-oncology and vaccines franchises in a set of earnings figures discussed in an investing-focused analysis dated August 28, 2026.
Within that topline, Keytruda generated $8.4 billion in revenue in Q2 2026, also up 5 percent compared with the same period a year earlier, underscoring how much of Merck's growth engine is now concentrated in this single PD-1 inhibitor.
The 5 percent revenue growth across the company, coupled with a similar percentage increase from Keytruda, paints a picture of stable expansion rather than breakneck acceleration, but the absolute scale of oncology sales at $8.4 billion in just one quarter puts Merck in a strong position relative to many large pharma peers.
Market data compiled in an earnings overview shows that Merck delivered an adjusted EPS result that beat the consensus estimate by $0.13 in Q2 2026, with actual EPS of negative $0.26 versus an expected negative $0.39, reflecting the impact of acquisition-related items and R&D spending on reported earnings.
That $0.13 EPS beat, alongside the mid-single-digit revenue growth, suggests that Merck managed to balance heavy investment in future oncology programs and mRNA-based vaccines while still staying ahead of Wall Street expectations for the quarter.
For investors following Merck's income profile, the combination of steady revenue growth and an earnings beat may reinforce confidence in the company’s ability to fund its clinical pipeline and maintain its dividend over time, even as patent cliffs and competitive pressures loom later in the decade.
Cancer vaccine trial and Keytruda indications expand
The biggest recent catalyst for Merck has been the announcement of positive phase 3 results for a personalized mRNA-based cancer vaccine used in combination with Keytruda in high-risk melanoma, with data showing a meaningful reduction in disease recurrence and spread compared with Keytruda alone in more than 1,000 patients per the August 29, 2026 reporting on the trial.
In the trial, the combination regimen improved recurrence-free survival and reduced the risk that melanoma would metastasize to other organs, signaling that Merck’s oncology strategy increasingly hinges on pairing its established immunotherapy backbone with innovative, individualized therapies.
Commentary on the trial results notes that shares of the two companies involved rose following the announcement, with Merck stock gaining more than 12 percent to reach an all-time high on the day of the news according to market coverage dated August 28, 2026.
That double-digit jump, combined with the subsequent 1.30 percent pullback to $147.60, means Merck stock is now trading only modestly below its recent peak, a typical pattern when the market digests a large positive surprise and then reassesses how much of the future opportunity should be capitalized into the share price immediately.
Beyond melanoma, Merck’s flagship drug Keytruda continues to gain new indications, including a July 10, 2026 approval that expanded its use in muscle-invasive bladder cancer by allowing combination therapy with Padcev in both neoadjuvant and adjuvant settings for a broader patient population.
The July 10, 2026 decision broadened Keytruda’s label from use only in cisplatin-ineligible patients to all adults with muscle-invasive bladder cancer who are candidates for cystectomy, a change that could support incremental revenue growth in a challenging oncology segment, as described in an August 28, 2026 update summarizing drug approvals.
For Merck, this expanded bladder cancer indication complements the melanoma vaccine combination data by reinforcing a strategy built on layering Keytruda across tumor types and lines of therapy, then enhancing its effect with targeted partners in specific disease settings.
Regulatory materials outline complex dosing schedules for Keytruda and Padcev in both neoadjuvant and adjuvant phases, but for investors the key takeaway is that Merck now has another approved pathway to generate long-duration treatment in a high-risk cancer population, potentially supporting multi-year revenue streams beyond the current Q2 2026 numbers.
Viewed together, the melanoma trial and bladder cancer label expansion suggest that Merck is working to sustain Keytruda’s value well into the next decade while also building a complementary vaccine-based platform that could mitigate the risk of upcoming patent expirations.
Stock performance and market reaction
Market quotes show that Merck shares have recently traded around $147.60, having declined 1.30 percent intraday in the latest session, even though the stock had earlier reached a high near $151, an all-time level highlighted in a same-day market portal report as of August 28, 2026.
Another intraday snapshot from a European financial news service indicated that Merck stock was down 1.3 percent to $147.59 at 8:26 p.m. local time on August 28, 2026, while a separate update at 4:28 p.m. local time showed a 0.8 percent loss at a price of $148.31, illustrating modest volatility as traders adjusted positions after the rally.
These prints place the latest price only a few dollars below the recent intraday high, suggesting that Merck stock is consolidating gains rather than reversing sharply, with the pullback more consistent with profit-taking after a headline-driven spike than with a fundamental reassessment of the company’s prospects.
Financial commentary dated August 28, 2026 also pointed out that Merck shares were trading at $148.35 during the session, reflecting a 0.80 percent decline, which aligns closely with the other intraday quotes and reinforces the picture of a stock moving within a narrow band after a much larger prior jump.
The fact that Merck’s price reaction to the melanoma vaccine news was more than 12 percent higher, compared with the day’s later 1.30 percent dip, underscores how the market initially priced in a major expansion of Merck's long-term oncology opportunity and then moved to balance enthusiasm with caution.
For long-term investors, the key numerical comparison is between the short-term share price movement and the company’s underlying earnings trajectory: a 12 percent rally on the headline contrasts with 5 percent year-over-year revenue growth and a $0.13 earnings beat, which may indicate that expectations for future growth extend well beyond the Q2 2026 baseline.
If Merck can sustain mid-single-digit revenue expansion while progressively adding new indications and combination regimens for Keytruda and its vaccine partner, the current price zone near the recent high could be justified; however, any setback in the phase 3 program or regulatory review would likely test how much optimism is embedded in the valuation.
Pipeline, patent risk and guidance context
Merck’s heavy reliance on Keytruda, which delivered $8.4 billion in Q2 2026 sales, inevitably brings patent risk to the foreground, and recent analysis of the company’s position notes that upcoming end-of-decade patent expirations for the drug have drawn scrutiny from investors.
Historically, a second-phase analysis of earlier trials suggested that the combination of the personalized vaccine and pembrolizumab reduced the risk of melanoma recurrence or death by 49 percent compared with pembrolizumab alone, a figure cited in background coverage of the cancer program as of August 28, 2026.
Although the latest phase 3 data have not yet been fully quantified in public, and companies have withheld exact efficacy numbers, the fact that the earlier 49 percent risk reduction figure exists as context helps investors benchmark expectations for the magnitude of benefit in the new study.
Given that Merck’s Q2 2026 revenue was $16.6 billion and that nearly half of its growth is tied to oncology and vaccine segments, any successful commercialization of the personalized melanoma vaccine alongside Keytruda could support a material impact on revenue over time, even if initial uptake is gradual.
Consensus estimates compiled in an earnings overview suggest that analysts expect Merck to continue posting steady revenue gains while navigating higher R&D spending and integration costs from pipeline deals, with the Q2 2026 EPS beat of $0.13 providing evidence that management is delivering against those expectations so far.
Investors will therefore watch upcoming events closely, particularly the next quarterly reporting date estimated around late October 2026, to see whether Merck’s guidance and commentary explicitly quantify the commercial potential of its personalized vaccine and expanded Keytruda indications.
While formal guidance figures for 2026 revenue and earnings were not detailed in the available materials, the combination of 5 percent year-over-year sales growth, an earnings beat, and a powerful oncology catalyst suggests that Merck may have room to tighten or raise its outlook once more data and regulatory milestones are secured.
Keytruda as the flagship oncology product
Keytruda, Merck’s PD-1-blocking antibody, has become the company’s flagship oncology product, and its central role in both Q2 2026 results and recent clinical developments makes it the most representative drug for understanding Merck’s current business model.
The Q2 2026 sales figure of $8.4 billion for Keytruda underscores how deeply this medicine is embedded across multiple cancer types, including melanoma, lung cancer, and bladder cancer, providing a diversified revenue base within oncology even as the company prepares for eventual biosimilar competition.
The July 10, 2026 bladder cancer label expansion, in which Keytruda is administered via IV infusion either every three weeks for four doses or every six weeks for two doses in the neoadjuvant phase, followed by extended dosing in the adjuvant phase when combined with Padcev, demonstrates how Merck is using complex regimen design to maximize treatment duration and clinical benefit.
Regulatory summaries highlight that Keytruda’s expanded bladder indication now covers adults who are cisplatin-eligible in addition to those previously approved as cisplatin-ineligible, meaning Merck’s potential patient pool in this indication has widened significantly as of July 10, 2026.
From an investor perspective, Keytruda’s vast indication footprint and ongoing trial portfolio make it both a strength and a concentration risk: the drug’s success underpins Merck’s growth, but patent expirations and competitive immunotherapies could challenge that dominance later in the decade.
The personalized mRNA vaccine program offers a partial hedge by positioning Merck at the forefront of individualized oncology treatments, potentially creating new proprietary assets and data exclusivity that complement Keytruda’s biologic patent protections.
Merck stock and investor takeaway
Merck stock trades on the New York Stock Exchange under the ticker MRK, reflecting its status as a large-cap U.S. pharma company with a significant oncology and vaccines franchise.
As of August 28, 2026, intraday market data show the shares around $147.60 in USD following a 1.30 percent decline from the session’s earlier high near $151, leaving the stock only modestly below its latest peak after a more than 12 percent rally tied to the melanoma vaccine news.
For investors, the current picture is defined by three key numbers: $16.6 billion in Q2 2026 revenue, 5 percent year-over-year growth, and $8.4 billion in Keytruda sales, all supported by a $0.13 EPS beat and a powerful new cancer vaccine catalyst that drove Merck stock to an all-time high before the recent pullback.
Fact box
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: New York Stock Exchange
Price (as of August 28, 2026, 11:02 a.m. ET): $147.60 USD
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
